Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linsitinib and Erlotinib with Radiation for cSCCHN
NCT01465815Phase 2Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Dec 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linsitinib in squamous cell carcinoma of the skin (SCC), sponsored by OHSU Knight Cancer Institute. Planned start Dec 2011; status: withdrawn.
02
Drugs
linsitinib
03
Conditions
squamous cell carcinoma of the skin (SCC)
Beyond the preview
Go deeper on NCT01465815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01465815.